tissue improvement
One Dose, Months of Relief: Eupraxia’s EoE Breakthrough
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) put out an update on its RESOLVE study this week, and the results look encouraging, at least at this stage. The company shared new tissue and symptom data from patients treated with EP-104GI for eosinophilic esophagitis, a condition that remains difficult to treat long term. What stands out most is how…
